Key points from article :
Six melanoma patients given an experimental, custom-made, neoantigen vaccine.
None of their tumours returned after treatment.
Custom vaccine created by sequencing the DNA of the tumour cells and searching for mutations.
Algorithms then identify which mutations to make antigens for the immune system to attack.
Two years after treatment the patients’ blood still carried anti-melanoma T cells.
The study was published in the Nature journal.
